US2003114370A1PendingUtilityA1

Nucleic acid molecules encoding endostatin protein and peptide fragments thereof

59
Priority: Oct 23, 1995Filed: Jan 11, 2002Published: Jun 19, 2003
Est. expiryOct 23, 2015(expired)· nominal 20-yr term from priority
Inventors:M. Judah FolkmanMichael S. O'Reilly
C07K 14/78A61K 38/00A61P 9/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Endostatin compositions capable of inhibiting endothelial cell proliferation, inhibiting angiogenesis and causing tumor regression are described. Specifically, amino acid sequences of endostatin proteins and nucleic acid sequences coding for endostatin proteins are provided.

Claims

exact text as granted — not AI-modified
1 . An isolated endostatin protein, wherein the protein has an amino acid sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:5.  
     
     
         2 . The endostatin protein of  claim 1  having an amino acid sequence of SEQ ID NO:3.  
     
     
         3 . The endostatin protein of  claim 1  having an amino acid sequence of SEQ ID NO:5.  
     
     
         4 . The endostatin protein of  claim 1  made by a process comprising, recombinantly producing the protein of  claim 1  in a recombinant expression system, and isolating the recombinantly produced protein in its un-refolded form.  
     
     
         5 . The endostatin protein of  claim 4 , wherein the endostatin protein has an amino acid sequence of SEQ ID NO:3.  
     
     
         6 . The endostatin protein of  claim 4 , wherein the endostatin protein has an amino acid sequence of SEQ ID NO:5.  
     
     
         7 . The endostatin protein of  claim 4 , wherein the recombinant expression system is selected from the group consisting of bacterial expression systems, yeast expression systems and insect viral expression systems.  
     
     
         8 . The endostatin protein of  claim 7 , wherein the recombinant expression system is  E. coli,  Pichia, or baculovirus.  
     
     
         9 . An isolated nucleic acid molecule having a sequence encoding an endostatin protein, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6.  
     
     
         10 . The isolated nucleic acid molecule of  claim 9  having the sequence of SEQ ID NO:4.  
     
     
         11 . The isolated nucleic acid molecule of  claim 9  having the sequence of SEQ ID NO:6.  
     
     
         12 . The composition of  claim 6 , further comprising, a vector containing the nucleic acid sequence encoding endostatin protein, wherein the vector is capable of expressing an endostatin protein when present in a cell.  
     
     
         13 . The composition of  claim 9 , wherein the nucleic acid has a sequence of SEQ ID NO:4.  
     
     
         14 . The composition of  claim 9 , wherein the nucleic acid has a sequence of SEQ ID NO:6.  
     
     
         15 . The endostatin protein of  claim 1 , further comprising a pharmaceutically acceptable excipient.  
     
     
         16 . The endostatin protein of  claim 15 , wherein the endostatin protein has a sequence of SEQ ID NO:3.  
     
     
         17 . The endostatin protein of  claim 15 , wherein the endostatin protein has a sequence of SEQ ID NO:5.  
     
     
         18 . The composition of  claim 15 , wherein the composition provides a sustained release of the endostatin protein for a period of at least 8 hours.  
     
     
         19 . The endostatin protein of  claim 15 , wherein the protein is administered to an individual for the treatment of an angiogenesis-related disease.  
     
     
         20 . The endostatin protein of  claim 15 , wherein the angiogenesis-related disease is an angiogenesis-dependent cancer.

Join the waitlist — get patent alerts

Track US2003114370A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.